TORONTO, June 22 /CNW/ - Spectral Diagnostics Inc.("Spectral"), (TSX:
SDI), today announced the signing of a distribution agreement for commercial
sales of its novel sepsis test, the Endotoxin Activity Assay ("EAA(TM)), in
Italy. Estor, SpA ("Estor"), a leading supplier of in vitro diagnostic
technologies, will distribute Spectral's new assay instrument and its reagents
for use in emergency departments and intensive care units. Estor is also the
exclusive Italian distributor of Toray Medical's endotoxin removal system.
Spectral entered into a combined diagnostic and therapeutic strategic alliance
with Toray earlier this month for the management of severe sepsis.
"We are very pleased to be working with Estor to distribute our sepsis
assay throughout Italy. The EAA (TM) has been evaluated successfully in a
number of hospitals in Italy over the last year. Estor will be distributing a
next generation platform for the assay which is small and simpler to operate,
allowing access to new markets for the test", stated Dr. Paul Walker,
President and CEO of Spectral.
Spectral is a developer of innovative technologies for rapid diagnostics.
Spectral provides accurate and timely information to clinicians enabling the
early initiation of appropriate and targeted therapy. Current products include
rapid diagnostics for sepsis (EAA(TM)) and West Nile Virus as well as a range
of other biological reagents. Spectral's common shares are listed on The
Toronto Stock Exchange: SDI.
Information in this news release that is not current or historically
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, the future outlook
of Spectral and anticipated events or results are assumptions based on beliefs
of Spectral's senior management as well as information currently available to
it. While these assumptions were considered reasonable by Spectral at the time
of preparation, they may prove to be incorrect. Readers are cautioned that
actual results are subject to a number of risks and uncertainties, including
the availability of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Spectral to take
advantage of business opportunities in the biomedical industry, the granting
of necessary approvals by regulatory authorities as well as general economic,
market and business conditions, and could differ materially from what is
currently expected.
%SEDAR: 00002006E
